Shareholders to Vote on 7% Potential Dilution for Incentive Plan; CEO Compensation Exceeds $32M
Summary
Bausch & Lomb is seeking shareholder approval for a 25 million share increase in its incentive plan, representing approximately 7% potential dilution, while disclosing CEO compensation over $32 million and a significant modification to his equity awards.
Key Events
-
Proposed Share Pool Increase
Shareholders will vote on Proposal 3 to amend and restate the 2022 Omnibus Incentive Plan, increasing the authorized shares for issuance by an additional 25,000,000 common shares. This represents approximately 7% potential dilution based on current outstanding shares.
-
CEO Compensation and Equity Modification
CEO Brenton L. Saunders' total compensation for 2025 was $32,194,326. His New Hire PSUs were modified in 2025, resulting in an incremental fair value of $12,862,500, to ensure continued employment terms are not contingent on the BHC spin-off and to adjust performance metrics.
-
Board Refreshment
Two new independent directors, Dr. Eduardo Alfonso and Mr. Steven H. Collis, were appointed effective January 1, 2026, replacing Messrs. Icahn and Hu who resigned in 2025. The board is now 90% independent.
-
Annual Shareholder Meeting Scheduled
The 2026 Annual Meeting of Shareholders will be held virtually on Wednesday, May 20, 2026, at 10:30 a.m. Eastern Daylight Time, where shareholders will vote on the proposals.
Analysis
Bausch & Lomb's definitive proxy statement outlines key proposals for its upcoming annual meeting, most notably a request for shareholder approval to increase the Omnibus Incentive Plan's share reserve by 25 million common shares. This represents a significant potential dilution of approximately 7% of current outstanding shares, which could impact shareholder value. Additionally, the filing details substantial executive compensation, with CEO Brenton L. Saunders' total compensation for 2025 exceeding $32 million. A notable modification to his New Hire PSUs, valued at an incremental $12.86 million, was made to ensure executive retention and align incentives with long-term performance, independent of the Bausch Health Companies Inc. spin-off timing. Investors should carefully consider the dilutive impact of the proposed share increase and the structure of executive compensation.
At the time of this filing, BLCO was trading at $16.49 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $10.45 to $18.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.